Timing, Geography, and Pragmatic Risk Reduction in Prevention of Medication-Related Osteonecrosis of the Jaw During Low-Dose BMA Therapy
Open Access
Abstract
Prevention of medication-related osteonecrosis of the jaw (MRONJ) associated with low-dose bone-modifying agents (LD-BMAs) remains a clinically relevant challenge, particularly due to the heterogeneity of recommendations and the growing number of patients exposed to these therapies. Unlike high-dose regimens, LD-BMAs are associated with a lower incidence and longer latency of MRONJ, generating uncertainty regarding the optimal timing and scope of dental interventions. This commentary critically compares four major international position papers and consensus documents (AAOMS 2022, SIPMO–SICMF 2020/2024, Chinese Expert Consensus 2024, and SIOT–SIdP 2023) through four pragmatic questions concerning patient stratification, timing of dental assessment, speed of risk reduction, and the role of prescriber-oriented screening tools. The analysis highlights substantial discrepancies among preventive models, particularly regarding whether pre-treatment dental treatments should be mandatory or whether early post-initiation assessment may be acceptable in selected low-risk patients.Keywords
This publication has 9 references indexed in Scilit:
- Medication-Related Osteonecrosis of the Jaw: An Evidence-Based 2025 Position Statement from a Korean Multidisciplinary Task ForceEndocrinology and Metabolism, 2025
- Medication related osteonecrosis (MRONJ) in the management of CTIBL in breast and prostate cancer patients. Joint report by SIPMO AND SIOMMMSJournal of Bone Oncology, 2024
- Chinese expert consensus on the diagnosis and clinical management of medication-related osteonecrosis of the jawJournal of Bone Oncology, 2024
- Italian position paper ( SIPMO‐SICMF ) on medication‐related osteonecrosis of the jaw ( MRONJ )Oral Diseases, 2024
- Anti-resorptive therapy in the osteometabolic patient affected by periodontitis. A joint position paper of the Italian Society of Orthopaedics and Traumatology (SIOT) and the Italian Society of Periodontology and Implantology (SIdP)Journal of Orthopaedics and Traumatology, 2023
- MRONJ in breast cancer patients under bone modifying agents for cancer treatment-induced bone loss (CTIBL): a multi-hospital-based case seriesBMC Oral Health, 2023
- American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 UpdateJournal of Oral and Maxillofacial Surgery, 2022
- Medication-Related Osteonecrosis of Jaws (MRONJ) Prevention and Diagnosis: Italian Consensus Update 2020International Journal of Environmental Research and Public Health, 2020
- Alveolar bone histological necrosis observed prior to extractions in patients, who received bone‐targeting agentsOral Diseases, 2020